Study title: Dockhorn−R−J, Williams−B−O, Sanders−R−L. Efficacy of acrivastine with pseudoephedrine in treatment of allergic rhinitis due to ragweed. Annals of allergy asthma & immunology : official publication of the American College of Allergy Asthma & Immunology, {Ann−Allergy−Asthma− Immunol}, Feb 1996, vol. 76, no. 2, p. 204−8.Dockhorn−R−J, Williams−B−O, Sanders−R−L. Efficacy of acrivastine with pseudoephedrine in treatment of allergic rhinitis due to ragweed. Annals of allergy asthma & immunology : official publication of the American College of Allergy Asthma & Immunology, {Ann−Allergy−Asthma− Immunol}, Feb 1996, vol. 76, no. 2, p. 204−8.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases [C08] | |||||
| Brands: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: ACRIVASTIN AND PSEUDOEPHEDRINE | |||||
| ATC code: RO1BA | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |